- Paper Report
- Open Access
CTLA-4 blocks activation of arthritogenic T cells
- Richard Brasington1
© Current Science Ltd 2000
- Published: 19 October 2000
- collagen induced arthritis
- gene therapy
A second "costimulatory" signal is required for T cell activation; the prototype T cell costimulatory receptor is CD28. Cytotoxic T lymphocyte associated antigen (CTLA)-4 downregulates activated T cells via a soluble form (CTLA-4Ig) which blocks CD28 signalling. CTLA-4Ig delivered intravenously is being evaluated as a treatment for rheumatoid arthritis. This study examines the effects of adenovirally delivered CTLA-4Ig in the treatment of established collagen-induced arthritis (CIA).
The authors conclude that gene therapy with soluble CTLA-4 effectively blocks activation of arthritogenic T cells in vivo. Treatment CTLA-4Ig suppressed CIA in a dose-dependent manner.
Gene transfer mediated by replication-deficient recombinant adenovirus, chimeric CTLA-4Ig fusion protein, DBA/1 mice